CHILLICOTHE ― Bird flu may have been found in waterfowl at Yoctangee Park. According to Andy Chow, communications chief at the Ohio Department of Natural Resources, the Division of Wildlife ...

Since late 2024, the avian influenza virus H5N1 has been spreading rapidly through wild bird populations, possibly spurred by fall migration. Waterfowl and seabirds have been hit hard, though ...

"Every crew has a special crew name, and this crew has named themselves a Perfect 10. Well, that makes perfect sense to me, considering the fact that this is, in fact, our 10th human flight." Blue ...

Every product is carefully selected by our editors and experts. If you buy from a link, we may earn a commission. Learn more. For more information on how we test products, click here. Enter Levi’s, ...

JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement to be taken private. The firm expects a completed ...

In AT&T’s case, the carrier used a BlueBird satellite to power a video call from a phone in Midland, Texas, to another device in Dallas, while harnessing the carrier’s radio spectrum.

Forbes contributors publish independent expert analyses and insights. I write about the world of biology.

All poultry flocks on the island of Ireland are in lockdown after a “housing order” was imposed a week ago. This is the season for case spikes. Avian flu was detected in a small number of ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million. Bluebird on ...

A pair of in­vestors will ac­quire blue­bird bio in a deal worth on­ly $29 mil­lion up­front af­ter the gene ther­a­py mak­er ran out of time … ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly traded company. The agreement comes after years of financial ...

bluebird bio (NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private ...